AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05865210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kegel Exercise
Description: Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
Study NCT05865210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kegel Exercise
Description: Kegel exercises (also called pelvic floor exercises) will be used to strengthen the pelvic floor muscles it will involve repeatedly contracting and relaxing the muscles that form part of the pelvic floor.
Study NCT05865210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release technique
Description: Myofasical release will include deep pressure for 10-15 seconds to release the trigger points and also gentle, light soft tissue massage on the vaginal muscles and surrounding areas.
Study NCT05041062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immunotherapy drug (a type of drug that helps your immune system fight cancer) that is often used with ipilimumab as the first treatment in adults with mesothelioma whose disease cannot be removed by surgery. The drug will be given as an IV infusion.
Study NCT05041062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a type of immunotherapy drug known as a checkpoint inhibitor, which helps your own immune system attack cancer cells.
Study NCT04848597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-PD-1 monoclonal antibody injection
Description: 200mg , once every 3 weeks
Study NCT05037071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper body graduated compression sleeve
Description: An over the counter light compression sleeve will be worn during game training
Study NCT04614909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 60mg administered orally BID for 4 days prior to surgical resection
Study NCT04614909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 200mg administered orally BID for 4 days prior to surgical resection
Study NCT04614909 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients in Phase 2 will receive 6-7 weeks of radiation therapy per standard of care
Study NCT04614909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Arm A and Arm B participants after RT is completed, will receive pamiparib in combination with TMZ (newly diagnosed participants). Arm C participants will receive olaparib with TMZ.
Study NCT04897022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Fixed dose of pembrolizumab 200mg IV q3 weeks
Study NCT04897022 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMPRINT
Description: The starting radiation dose will consist of 400cGy x5 fractions. Doses will be escalated by 100cGy per fraction (i.e. 400cGy, 500cGy, 600cGy) for a total of 3 dose levels. The MTD will be evaluated using a modified Continuous Reassessment Method. Dose limiting toxicities (DLTs) are defined as any treatment-related non-hematologic toxicity with a CTCAE v5 Grade ≥3 or grade ≥2 pneumonitis that requires use of steroids occurring after the start of IMPRINT through the first 3 months after the last fraction.
Study NCT06443892 — intervention group
Intervention type: PROCEDURE
Intervention: Pericapsular Nerve Block (PENG)
Description: Evaluation of postoperative analgesic efficacy of PENG block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
Study NCT06443892 — intervention group
Intervention type: PROCEDURE
Intervention: Suprainguinal Fascia Iliaca Compartment Block (SFICB)
Description: Evaluation of postoperative analgesic efficacy of SFICB block in participants with intertrochanteric femur fractures undergoing surgery under spinal anesthesia.
Study NCT06048809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride Toothpaste (Sensodyne Repair and Protect)
Description: Sensodyne Repair and Protect toothpaste containing 1100 ppm fluoride as SnF2.
Study NCT06048809 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Fluoride Toothpaste (Colgate Cavity Protection)
Description: Colgate Cavity Protection containing 1100 ppm fluoride as SMFP.
Study NCT04871477 — intervention group
Intervention type: OTHER
Intervention: Communication Intervention
Description: Audio record part of clinic visit
Study NCT04871477 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06249841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1.1mm flexible Cryoprobe SU
Description: Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
Study NCT04765956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon treatment
Description: Drug-eluting balloon (DEB) treatment of lipid-rich plaque
Study NCT05870670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Administered subcutaneously.
Study NCT06249841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1.1mm flexible Cryoprobe SU
Description: Six tissue samples retrieved by standard biopsy forceps and three samples by cryobiopsy (randomized sequence)
Study NCT06138899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Club 25
Description: The Club 25 donation program will involve students pledging to donate blood 25 times in their lifetime. In order to achieve this objective, students also pledge to lead a healthy lifestyle, to avoid acquiring HIV and other TTIs and to continue donating blood after leaving school. The Club 25 donation program includes activities in-between blood donation events as well as peer leadership and peer education in schools and in communities.
Study NCT05870670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously.
Study NCT05571904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thick STSG; thin STSG
Description: For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients.
Study NCT05571904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thick STSG; thin STSG
Description: For all the patients, thick STSGs (at a depth of 0.7 mm) were harvested from the upper lateral thighs to repair skin defects at functional sites or joint sites. For patients in the thick STSG group, the surgeons harvested a larger size of thick STSGs than the size of recipient sites. The size of the donor site was 150% - 200% of the size of the recipient site. Part of the thick STSG was grafted onto the recipient site. Subsequently, the leftover skin was punctured (in 1.5:1 mesh ratio) and stretched to obtain expansion. The donor site was covered by the leftover skin completely. In other words, the donor site was reconstructed by resurfacing the large sheet of thick STSG in situ.~For patients in the thin STSG group, the surgeons harvested thick STSGs of the size of recipient sites. Their donor sites were covered with a large sheet of thin STSGs (at a depth of 0.4 mm) which were harvested from other parts of the patients.
Study NCT06788223 — intervention group
Intervention type: DEVICE
Intervention: Parathyroidectomy
Description: Parathyroidectomy under general anesthesia
Study NCT06524635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Description: Subcutaneous (SC) Injection
Study NCT04829110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Participants will consume sucrose in solution with water
Study NCT06060496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active cTBS
Description: Two cTBS sessions (each session delivering 3600 pulses) separated by 50 minutes
Study NCT05994001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cardonilizumab
Description: cardonilizumab:PD1 and CTLA-4 bispecific antibody
Study NCT05994001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-302
Description: LM-302 :ClAUDIN 18.2-ADC
Study NCT06160297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Otago Exercise
Description: The exercises are as follows;~Warm-up exercises (5 min)~Strengthening exercises (weight attached to ankle)~* Knee extension while sitting on a chair~* Knee flexion while standing with support from a chair~* Hip abduction while standing with support from the chair~Strengthening exercises (weight removed from ankle)~* Standing on tiptoe with support from a chair~* Rising on the heels with support from a standing chair~Balance Exercises (progressively, with support - without support)~* Mini squats~* Toe walking~* Walking on heels~* Tandem stance~* Tandem walking~* Walking backwards (10 steps)~* Standing on one leg~* Assisted side walking~* Side walking without support~* Sit and stand on the chair~* Figure eight walking
Study NCT06160297 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise
Description: * Proprioceptive stabilization of the knee with ball~* Bridging with ball~* Stepping forward, sideways and backwards by holding on to a fixed support while standing~* Doing the same movements with the support leg on a different surface~* Hip abduction-adduction with resistance band~* Knee flexion-extension with resistance band~* Climbing and descending steps by taking steps~* Balancing on the step~* Standing up from the chair
Study NCT05237336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences.
Study NCT05237336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based Cognitive Therapy
Description: MBCT is a relapse prevention program that is used to teach participants with chronic physical/mental ailment (used to their conditions):~* to manage early signs of distresses with compassionate awareness, and respond more effectively to mood and cognitive changes.~* To become aware of bodily sensations, feelings, and thoughts, from moment to moment.~* To help participants learn different ways of relating to sensations, thoughts and feelings- through mindful acceptance and acknowledgement of unwanted feelings and thoughts, rather than habitual, automatic, preprogrammed routines that tend to perpetuate difficulties.~* To help participants to be able to choose the most skilful response to any unpleasant thoughts, feelings or situations that they meet.~UK's NICE recommends MBCT for persons who are well and have had 3 or more episodes of depression. MBCT benefits persons whose distress is triggered by the way they process experiences.
Study NCT05237336 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counselling as usual
Description: Control group, Counselling as usual
Study NCT04683744 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews-Patients
Description: The interview guide will consist of questions to elicit the patients thoughts about getting preventive healthcare during the COVID-19 pandemic, including perception of risk, barriers to getting healthcare, and information needed for decision making.
Study NCT04683744 — intervention group
Intervention type: OTHER
Intervention: Semi-structured interviews-Health system
Description: The interview guide will consist of questions to elicit thoughts from health system leadership, providers, and staff about implementing decision aids, provider notifications, and cancer risk assessments in their health center or healthcare system. The questions may be specific to colorectal cancer screening or more generally about other cancer screenings. The investigators may also ask questions about cancer screening initiatives their health center or healthcare system engaged in during the COVID-19 pandemic.
Study NCT06060496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham cTBS
Description: Two sham cTBS sessions (sham mimics the experimental session but does not deliver any electricity to the brain) separated by 50 minutes
Study NCT06347965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low load blood flow restriction training
Description: Low load blood flow restriction training will be conducted on the subjects three times a week. Each training session includes upper and lower limb training, with 4 groups trained and repeated 30, 15, 15, and 15 times for each group. Train for a total of 12 weeks.The resistance strength will remain at 30% RM for weeks 1-12.
Study NCT06347965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training group
Description: The subjects will undergo progressive resistance training three days a week, three groups per day, with each group repeating 10 times. Training includes upper and lower limbs. The resistance load increases over time, with a resistance load of 30% RM for weeks 1-4, 50% RM for weeks 5-8, and 70% RM for weeks 9-12.
Study NCT05601050 — intervention group
Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study NCT04925947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 will be given intravenously at 5 mg/kg every 2 weeks. A cycle is defined as 2 treatments (28 days). Treatment will be given until progression, excessive toxicity, or up to two years.
Study NCT05109078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]- Rongliflozin
Description: Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1
Study NCT06453863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Greater plantar feedback shoes
Description: Shoes providing enhanced plantar feedback
Study NCT06453863 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral gym shoes
Description: Regular gym shoes
Study NCT06453863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barefoot
Description: For the acute evaluation, barefoot will be considered as an active comparator for enhanced plantar feedback
Study NCT05833568 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial alternative current stimulation
Description: GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~tACS stimulation will be applied for 20 minutes for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the tACS condition.
Study NCT05833568 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Transcranial alternative current stimulation
Description: GTEN 200 (Magstim-EGI, OREGON, USA). The current will be administered via an amplifier connected to an EEG system of 128-Channel Geodesic Sensor Net (Magstim-EGI, Oregon, USA) with sponge-based electrode nets.~SHAM stimulation will be applied for a 2-minute ramp-up, then the current will stop for 20 minutes, followed by a 2-minute ramp-down. This will be applied for 5 consecutive days via a bilateral electrode montage of 5 electrodes per hemisphere over parieto-occipital cortical sites. Specific stimulation electrodes for both conditions will be: \[right hemisphere: E83, E90, E96, E84, E91\] and for the \[left hemisphere: E58, E65, E70, E66, E59\]. The intensity of the applied alternative current (AC) will be a maximum of 1 mA peak-to-peak. The stimulation frequency will be adjusted to 10 Hz (median value of the alpha frequency band) for the ramp-up and down in the SHAM conditions.
Study NCT03877991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-sesame oil capsule
Description: A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
Study NCT03877991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-LNL capsule
Description: A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
Study NCT03877991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD powder form capsule
Description: Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
Study NCT06417736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate 40 MG
Description: 160mg/one time/day
Study NCT06207305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by PO
Study NCT06207305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by PO
Study NCT06207305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Given by PO
Study NCT06207305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by PO
Study NCT05767021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV
Study NCT05767021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study NCT06193863 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: At the discretion of the treating physician, based on the recommendations written in the local product information.
Study NCT06430385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION440
Description: ION440 will be administered by intrathecal bolus (ITB) injection.
Study NCT06430385 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
Study NCT05669547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual hormone fully closed loop (DHFCL)
Description: dual hormone fully closed loop consisting of an algorithm, sensors and both insulin and glucagon infusion.
Study NCT04975308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.
Study NCT04975308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Administered orally.
Study NCT04975308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Administered IM.
Study NCT04975308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT05564221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35324
Description: Subcutaneous injection of YH35324
Study NCT05564221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of None of active ingredient
Study NCT05564221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subcutaneous injection of Omalizumab
Study NCT03746535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Study NCT03746535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elagolix
Description: Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Study NCT05465616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viome's Precision Nutrition Program (VPNP)
Description: Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Study NCT05337228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-C006 Peri inj.
Description: IN-C006 peri inj. will be injected continuously for 3 days.
Study NCT05337228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPN301
Description: RPN301 will be injected continuously for 3 days.